Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study

Outcomes for children with relapsed or refractory acute myeloid leukaemia remain poor. The BCL-2 inhibitor, venetoclax, has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older adults for whom chemotherapy is not suitable with newly diagnosed acute mye...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology Jg. 21; H. 4; S. 551 - 560
Hauptverfasser:	Karol, Seth E, Alexander, Thomas B, Budhraja, Amit, Pounds, Stanley B, Canavera, Kristin, Wang, Lei, Wolf, Joshua, Klco, Jeffery M, Mead, Paul E, Das Gupta, Soumyasri, Kim, Su Y, Salem, Ahmed Hamed, Palenski, Tammy, Lacayo, Norman J, Pui, Ching-Hon, Opferman, Joseph T, Rubnitz, Jeffrey E
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.04.2020 Elsevier Limited
Schlagworte:	Acute myeloid leukemia Adolescent Antineoplastic Combined Chemotherapy Protocols - administration & dosage Bcl-2 protein Bone marrow Bridged Bicyclo Compounds, Heterocyclic - administration & dosage Chemotherapy Child Child, Preschool Children Colitis Cytarabine Cytarabine - administration & dosage Female Fungal infections Hematology Hematology, Oncology, and Palliative Medicine Humans Idarubicin - administration & dosage Intravenous administration Invasiveness Leukemia Leukemia, Myeloid, Acute - drug therapy Male Neoplasm Recurrence, Local - drug therapy Neutropenia Neutrophils Patients Remission Sepsis Stem cells Sulfonamides - administration & dosage Transplants & implants Young Adult United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!